We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Varian & Tata Trust Tie Up to Boost Radiotherapy in India
Read MoreHide Full Article
Varian Medical Systems, Inc. recently announced signing of a three-year agreement with Tata Trust. The deal aims at increasing patient access to advanced radiation therapy treatments in India. This apart, Varian’s ARIA oncology information system and Eclipse treatment planning system will be implemented to help improve the level of care.
Following the announcement, shares of the Zacks Rank #2 (Buy) company gained 0.5% to $134.60 at close.
About the Agreement
The latest agreement is a part of a program undertaken by Tata Trusts with the goal of creating patient-centric cancer institutions and providing affordable care closer to patients' homes across different regions in India. This is likely to fortify Varian’s foothold in the Asia-Pacific radiation therapy market as India is expected to witness 1.8 million new cancer cases a year by 2025.
Varian’s Presence in India
It is encouraging to note that Mumbai’s first Varian Edge radiosurgery system was installed in 2016. In the same year, this California-based MedTech giant was selected by India’s Apollo Hospitals Group for the supply of 12 advanced medical linear accelerators and five brachytherapy systems to replace traditional cancer treatment machines.
The company’s Advanced Radiotherapy Clinical School is currently running courses at the Reliance Group's flagship Kokilaben Dhirubhai Ambani Hospital in Mumbai. (Read More: Varian & Reliance Group Tie Up to Enhance Cancer Care)
Additionally, last October, the first lung cancer patient in India was treated with Varian’s popular Halcyon system in Gujarat’s Sterling Cancer Hospital.
Another MedTech company that has a solid presence in the Indian cancer care space is Accuray Incorporated (ARAY - Free Report) . Notably, the company’s flagship Radixact system currently experiences robust demand across the country.
Market Prospects
Market Data Forecast predicts that the Asia-Pacific radiotherapy market is expected to witness a CAGR of 6.8% to reach $1.79 billion by 2023.
Growth of the aging population, technological innovations in radiotherapy products and increasing cases of cancer are currently fueling the market’s growth.
In this scenario, we believe the latest development to be a well-timed one for Varian.
Price Performance
In a year’s time, the stock has rallied 6.4% compared with the industry’s 4.4% growth. The current level is also higher than the S&P 500 index’s 1.3% decline.
Stryker’s long-term earnings growth rate is projected at 10%.
DexCom’s current-quarter earnings growth rate is expected to be 46.9%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Varian & Tata Trust Tie Up to Boost Radiotherapy in India
Varian Medical Systems, Inc. recently announced signing of a three-year agreement with Tata Trust. The deal aims at increasing patient access to advanced radiation therapy treatments in India. This apart, Varian’s ARIA oncology information system and Eclipse treatment planning system will be implemented to help improve the level of care.
Following the announcement, shares of the Zacks Rank #2 (Buy) company gained 0.5% to $134.60 at close.
About the Agreement
The latest agreement is a part of a program undertaken by Tata Trusts with the goal of creating patient-centric cancer institutions and providing affordable care closer to patients' homes across different regions in India. This is likely to fortify Varian’s foothold in the Asia-Pacific radiation therapy market as India is expected to witness 1.8 million new cancer cases a year by 2025.
Varian’s Presence in India
It is encouraging to note that Mumbai’s first Varian Edge radiosurgery system was installed in 2016. In the same year, this California-based MedTech giant was selected by India’s Apollo Hospitals Group for the supply of 12 advanced medical linear accelerators and five brachytherapy systems to replace traditional cancer treatment machines.
The company’s Advanced Radiotherapy Clinical School is currently running courses at the Reliance Group's flagship Kokilaben Dhirubhai Ambani Hospital in Mumbai. (Read More: Varian & Reliance Group Tie Up to Enhance Cancer Care)
Additionally, last October, the first lung cancer patient in India was treated with Varian’s popular Halcyon system in Gujarat’s Sterling Cancer Hospital.
Another MedTech company that has a solid presence in the Indian cancer care space is Accuray Incorporated (ARAY - Free Report) . Notably, the company’s flagship Radixact system currently experiences robust demand across the country.
Market Prospects
Market Data Forecast predicts that the Asia-Pacific radiotherapy market is expected to witness a CAGR of 6.8% to reach $1.79 billion by 2023.
Growth of the aging population, technological innovations in radiotherapy products and increasing cases of cancer are currently fueling the market’s growth.
In this scenario, we believe the latest development to be a well-timed one for Varian.
Price Performance
In a year’s time, the stock has rallied 6.4% compared with the industry’s 4.4% growth. The current level is also higher than the S&P 500 index’s 1.3% decline.
Other Key Picks
Other top-ranked stocks in the broader medical space are Stryker Corporation (SYK - Free Report) and DexCom (DXCM - Free Report) , each carrying a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Stryker’s long-term earnings growth rate is projected at 10%.
DexCom’s current-quarter earnings growth rate is expected to be 46.9%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>